FDG-PET-CT and Biomarkers in Esophageal Cancer

Inclusion Criteria:

1. Patient must have histologic documentation of adenocarcinoma or squamous carcinoma of the esophagus at M. D. Anderson Cancer Center (MDACC).
2. Patients with localized carcinoma of the esophagus who have undergone standard testing and been evaluated by the multidisciplinary team at MDACC and are considered appropriate candidates for and are willing to undergo chemoradiation therapy followed by surgery at MDACC. Radiation may be delivered as proton or photon. These patients have clinical stage II or III cancers and they are considered medically fit to undergo surgery.
3. Patient must have undergone a baseline esophagealgastroduodenoscopy (EGD) with biopsy and endoscopic ultrasonography at MDACC, with tissue available for biomarker analysis.
4. Patient must have undergone a baseline FDG-PET/CT at MDACC or an outside institution.
5. Patient must be willing to undergo a research "early" FDG-PET/CT (12 +/- 2 days from the start of chemoradiation).
6. Patient must provide written informed consent.
7. Patient must be \>/= 18 years of age.

Exclusion Criteria:

1. Patient is unable or unwilling to comply with the requirements of the protocol.
2. Patient had baseline FDG-PET/CT scan maximum SUV of \< 4.0.
3. Patient is not a candidate for chemoradiation followed by surgery.
4. Patients who received induction chemotherapy prior to chemoradiation therapy are excluded.
5. Patients with T1N0 or T4anyN are excluded.